130 related articles for article (PubMed ID: 11554164)
1. p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy.
Buglioni S; D'Agnano I; Vasselli S; Perrone Donnorso R; D'Angelo C; Brenna A; Benevolo M; Cosimelli M; Zupi G; Mottolese M
Am J Clin Pathol; 2001 Sep; 116(3):360-8. PubMed ID: 11554164
[TBL] [Abstract][Full Text] [Related]
2. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Chang SC; Lin JK; Lin TC; Liang WY
Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
[TBL] [Abstract][Full Text] [Related]
3. Bio-pathological factors of prognostic value in colorectal adenocarcinomas.
Mottolese M; Buglioli S; Piperno G; Sperduti I; Giannarelli D; D'Angelo C; Cosimelli M
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):163-6. PubMed ID: 16767924
[TBL] [Abstract][Full Text] [Related]
4. Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile.
Mottolese M; Orlandi G; Sperduti I; Merola R; Buglioni S; Di Benedetto A; Pinnarò P; Perracchio L; Venturo I; Cognetti F; Cianciulli A
Am J Surg Pathol; 2007 Feb; 31(2):247-54. PubMed ID: 17255770
[TBL] [Abstract][Full Text] [Related]
5. [A comparative study on the prognostic value of the nuclear expression of protein p53 vis-à-vis histopathology in colorectal cancer].
Díez M; Camuñas J; Enríquez JM; González A; Torabuela E; Gutiérrez A; Ratia T; Mugüerza JM; Martín A; Ruiz A; Granell J
An Med Interna; 1996 May; 13(5):222-6. PubMed ID: 8767868
[TBL] [Abstract][Full Text] [Related]
6. Stereologic estimates of volume-weighted mean nuclear volume in colorectal adenocarcinoma: correlation with histologic grading, Dukes' staging, cell proliferation activity and p53 protein expression.
Martín R; Nieto S; Santamaría L
Gen Diagn Pathol; 1997 Jul; 143(1):29-38. PubMed ID: 9269906
[TBL] [Abstract][Full Text] [Related]
7. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
Gal R; Sadikov E; Sulkes J; Klein B; Koren R
Dis Colon Rectum; 2004 Jul; 47(7):1216-24. PubMed ID: 15148649
[TBL] [Abstract][Full Text] [Related]
8. Influence of tumor localization on the prognostic value of P53 protein in colorectal adenocarcinomas.
Diez M; Medrano M; Mugüerza JM; Ramos P; Hernandez P; Villeta R; Martín A; Noguerales F; Ruiz A; Granell J
Anticancer Res; 2000; 20(5C):3907-12. PubMed ID: 11268475
[TBL] [Abstract][Full Text] [Related]
9. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
[TBL] [Abstract][Full Text] [Related]
10. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of four antibodies in detecting p53 protein for predicting clinicopathological and prognostic significance in colorectal adenocarcinoma.
Zhang Hong
Clin Cancer Res; 1999 Dec; 5(12):4126-32. PubMed ID: 10632350
[TBL] [Abstract][Full Text] [Related]
12. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma.
Bosari S; Viale G; Roncalli M; Graziani D; Borsani G; Lee AK; Coggi G
Am J Pathol; 1995 Sep; 147(3):790-8. PubMed ID: 7677190
[TBL] [Abstract][Full Text] [Related]
13. Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma.
Xie D; Sham JS; Zeng WF; Lin HL; Bi J; Che LH; Hu L; Zeng YX; Guan XY
Hum Pathol; 2005 Jul; 36(7):777-83. PubMed ID: 16084947
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.
Garrity MM; Burgart LJ; Mahoney MR; Windschitl HE; Salim M; Wiesenfeld M; Krook JE; Michalak JC; Goldberg RM; O'Connell MJ; Furth AF; Sargent DJ; Murphy LM; Hill E; Riehle DL; Meyers CH; Witzig TE;
J Clin Oncol; 2004 May; 22(9):1572-82. PubMed ID: 15117979
[TBL] [Abstract][Full Text] [Related]
15. DNA image cytometry predicts disease outcome in stage II colorectal carcinoma.
Buhmeida A; Hilska M; Elzagheid A; Laato M; Collan Y; Syrjänen K; Pyrhönen S
Anticancer Res; 2009 Jan; 29(1):99-106. PubMed ID: 19331138
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer.
Ahmed IA; Kelly SB; Anderson JJ; Angus B; Challen C; Lunec J
Colorectal Dis; 2008 May; 10(4):344-51. PubMed ID: 17949449
[TBL] [Abstract][Full Text] [Related]
17. Altered subcellular localization of suppressin, a novel inhibitor of cell-cycle entry, is an independent prognostic factor in colorectal adenocarcinomas.
Manne U; Gary BD; Oelschlager DK; Weiss HL; Frost AR; Grizzle WE
Clin Cancer Res; 2001 Nov; 7(11):3495-503. PubMed ID: 11705868
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas.
Bosari S; Viale G; Bossi P; Maggioni M; Coggi G; Murray JJ; Lee AK
J Natl Cancer Inst; 1994 May; 86(9):681-7. PubMed ID: 8158699
[TBL] [Abstract][Full Text] [Related]
19. DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study.
Bazan V; Migliavacca M; Zanna I; Tubiolo C; Corsale S; Calò V; Amato A; Cammareri P; Latteri F; Grassi N; Fulfaro F; Porcasi R; Morello V; Nuara RB; Dardanoni G; Salerno S; Valerio MR; Dusonchet L; Gerbino A; Gebbia N; Tomasino RM; Russo A
J Cancer Res Clin Oncol; 2002 Dec; 128(12):650-8. PubMed ID: 12474051
[TBL] [Abstract][Full Text] [Related]
20. The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
Tsamandas AC; Kardamakis D; Ravazoula P; Zolota V; Salakou S; Tepetes K; Kalogeropoulou C; Tsota I; Kourelis T; Makatsoris T; Karavias D; Scopa CD; Bonikos DS; Kalofonos HP; Petsas T
Strahlenther Onkol; 2004 Apr; 180(4):201-8. PubMed ID: 15057430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
